SCHEMBL4484877

SCHEMBL4484877

CCOC(=O)[C@@H]1CCC[C@@H]1NCC1CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.41
TAS1R1 Q7RTX1 2/20 0.41
JAK1 P23458 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CTSB P07858 1/20 0.38
PTGER4 P35408 1/20 0.36
PPM1B O75688 1/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4495311 0.97 TAS1R3 (0.41) TAS1R3TAS1R1JAK1MEN1KMT2A
SCHEMBL8441969 0.85 TAS1R3 (0.43) TAS1R3TAS1R1JAK1CTSBPPM1B
SCHEMBL4489974 0.85 TAS1R3 (0.43) TAS1R3TAS1R1JAK1CTSBPPM1B
SCHEMBL4485198 0.85 TAS1R3 (0.40) TAS1R3TAS1R1JAK1MEN1KMT2A
SCHEMBL4489935 0.85 TAS1R3 (0.40) TAS1R3TAS1R1JAK1MEN1KMT2A
SCHEMBL4485203 0.85 TAS1R3 (0.40) TAS1R3TAS1R1JAK1MEN1KMT2A
SCHEMBL4489932 0.85 TAS1R3 (0.40) TAS1R3TAS1R1JAK1MEN1KMT2A
SCHEMBL4485200 0.85 TAS1R3 (0.40) TAS1R3TAS1R1JAK1MEN1KMT2A
SCHEMBL4495502 0.80 JAK1 (0.46) TAS1R3TAS1R1JAK1CTSBPPM1B
SCHEMBL13712968 0.79 TAS1R3 (0.46) TAS1R3TAS1R1JAK1CTSBPPM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS HAVCR2, PYGL, HCCS TAS1R3 4286/4885TAS1R1 4108/4885JAK1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.